Endocrine complications in intensive care unit patients

Summary This review addressed end organ endocrine dysfunction or failure associated with diabetes, thyrid abnormalities, adrenal insufficiency, pheochromocytoma, and pituitary dysfunction, as well as the issue of corticosteroid replacement or pharmacologic application in the critically ill. Diabetes is a common cause that precipitates ICU admission or is a secondary factor in the routine care of the stressed and critically ill medical or surgical patient. Early identification of hypoglycemia is crucial to avoid potentially devastating neurologic sequale. Increasing data on the deleterious effects on immune function, wound healing, and recovery from ischemia has prompted the use of regular insulin infusions in acute and critically ill patients in an attempt to maintain euglycemia. 58 The large Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction trial reported the acute and long-term benefits of initial infusions of glucose, insulin, and potassium combined with tighter glycemic control in diabetics with acute myocardial infaretion. 15 DKA and NKHC share several common features and represent severe endpoints of abnormal glucose and fat metabolism. These entities require timely diagnosis and therapy and rapid identification of the inciting cause to limit morbidity and mortality. Cerebral edema is a relatively uncommon development in DKA, occurring most often in children and resulting in severe neurologic sequalae in many patients. Asymptomatic thyroid disease is fairly prevalant in the United States. Extremes of dysfunction may result in thyroid storm or myxedema coma, both requiring rapid identification and therapy. Thyroid hormone synthesis and peripheral metabllism and function are markedly altered in acute illness. The differentiation of thyroid activity has been markedly improved over the past several decades with the wide application of increasingly sensitive tests, such as the TSH, free T4, and free T3. The euthyroid sick syndrome is recognized as a “normal” physiologic response to critical illness. Supplementation with exogenous thyroid hormone in patients with euthyroid sick syndrome is not indicated and may be deleterious. Adrenal homeostasis is crucial for adequate response to life-threatening trauma or critical illness. The body is normally able to increase glucocorticoid release by a factor of roughly 10-fold. As the population ages and the use of corticosteroids increases, AI should be considered in any hemodynamically unstable patient. Relative AI is being recognized more commonly, particularly as a process in sepsis and septic shock. Recent preliminary data from an ongoing multicenter trial supports the short-term administration of physiologic, stress doses of glucocorticoids in such patients. Patients with pheochromocytoma, and uncommon chromaffin cell tumor, present to the ICU on occasion for acute diagnosis and initiation of therapy or for postoperative management. These tumors are most commonly adrenal in origin, secrete excessive norepinephrine, and may be associated with familial endocrinopathies. Alpha blockade is the mainstay of initial therapy followed by intravascular fluid expansion and judicious use of β blockade and calcium channel blockade in select patients. Pituitary pathology should be considered in patients with a period of significant shock; those who have undergone frontal craniotomy or pituitary resection; those who sustained head injury; or those with cerebral thrombosis who develop polyuria, hypothermia, electrolyte abnormalities, or hyperosmolarity. On occasion, nephrogenic DI develops in patients with renal pathology or secondary to medications, such as lithium or amphotericin B. Patients with central DI should be treated with fluids, have their serum sodium corrected, and receive DDAVP. Patients with suspected or known panhypopituitarism should be treated with appropriate doses of adrenal and thyroid hormone replacement.

[1]  K. Wood,et al.  Corticosteroid supplementation for adrenal insufficiency. , 2002, JAMA.

[2]  G. V. Berghe,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[3]  J. Kellum,et al.  Use of dopamine in acute renal failure: A meta-analysis , 2001, Critical care medicine.

[4]  J. Skatrud,et al.  Adrenal insufficiency in critically ill patients. , 2001, American journal of respiratory and critical care medicine.

[5]  N. Chaturvedi Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. , 2001, Annals of internal medicine.

[6]  W. Linehan,et al.  Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma , 2001, Annals of Internal Medicine.

[7]  R Malley,et al.  Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. , 2001, The New England journal of medicine.

[8]  C. Levetan Hospital management of diabetes , 2000, Endocrinology and metabolism clinics of North America.

[9]  D. Coursin,et al.  Perioperative Management of Selected Endocrine Disorders , 2000, International anesthesiology clinics.

[10]  W Zidek,et al.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. , 2000, The New England journal of medicine.

[11]  D. Annane,et al.  A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. , 2000, JAMA.

[12]  L. R. Sajja,et al.  Continuous intravenous insulin infusion reduces infections in diabetics after CABG. , 2000, The Annals of thoracic surgery.

[13]  Andrés Esteban,et al.  Accidental removal of endotracheal and nasogastric tubes and intravascular catheters , 2000, Critical care medicine.

[14]  A. Karchmer,et al.  Infections in patients with diabetes mellitus. , 1999, The New England journal of medicine.

[15]  J. Bertrand,et al.  Does bicarbonate therapy improve the management of severe diabetic ketoacidosis? , 1999, Critical care medicine.

[16]  J. Sowers,et al.  An update on perioperative management of diabetes. , 1999, Archives of internal medicine.

[17]  G. Meduri Levels of evidence for the pharmacologic effectiveness of prolonged methylprednisolone treatment in unresolving ARDS. , 1999, Chest.

[18]  G. Grunkemeier,et al.  Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. , 1999, The Annals of thoracic surgery.

[19]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[20]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[21]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[22]  G. Meduri,et al.  Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. , 1998, JAMA.

[23]  G. Meduri,et al.  Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. , 1998, Critical care medicine.

[24]  P. Bollaert,et al.  Reversal of late septic shock with supraphysiologic doses of hydrocortisone. , 1998, Critical care medicine.

[25]  J. Pomposelli,et al.  Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. , 1998, JPEN. Journal of parenteral and enteral nutrition.

[26]  D. Mangano,et al.  Renal Dysfunction after Myocardial Revascularization: Risk Factors, Adverse Outcomes, and Hospital Resource Utilization , 1998, Annals of Internal Medicine.

[27]  R. Hayward,et al.  Estimated Benefits of Glycemic Control in Microvascular Complications in Type 2 Diabetes , 1997, Annals of Internal Medicine.

[28]  H. Bruining,et al.  Corticosteroid therapy in severe illness. , 1997, The New England journal of medicine.

[29]  C. Berkey,et al.  Dexamethasone as Adjunctive Therapy in Bacterial Meningitis. A Meta-Analysis of Randomized Clinical Trials Since 1988 , 1997 .

[30]  H. Winn,et al.  Administration of Methylprednisolone for 24 or 48 Hours or Tirilazad Mesylate for 48 Hours in the Treatment of Acute Spinal Cord Injury Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial , 1997 .

[31]  J. Chesebro,et al.  Mechanisms Determining Course and Outcome of Diabetic Patients Who Have Had Acute Myocardial Infarction , 1997, Annals of Internal Medicine.

[32]  G. Grunkemeier,et al.  Glucose control lowers the risk of wound infection in diabetics after open heart operations. , 1997, The Annals of thoracic surgery.

[33]  D. Cook,et al.  Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. , 1995, Critical care medicine.

[34]  P. Ladenson,et al.  Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. , 1995, JAMA.

[35]  E. Bravo,et al.  Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. , 1994, Endocrine reviews.

[36]  B. Chernow,et al.  Perioperative Glucocorticoid Coverage A Reassessment 42 Years After Emergence of a Problem , 1994, Annals of surgery.

[37]  C. Buonocore,et al.  The diagnosis and management of diabetes insipidus during medical emergencies. , 1993, Endocrinology and metabolism clinics of North America.

[38]  L. Wartofsky,et al.  Life-threatening thyrotoxicosis. Thyroid storm. , 1993, Endocrinology and metabolism clinics of North America.

[39]  J. Nicoloff,et al.  Myxedema Coma: A Form of Decompensated Hypothyroidism , 1993 .

[40]  L. La Voie,et al.  Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. , 1990, The New England journal of medicine.

[41]  E. Ellis Concepts of fluid therapy in diabetic ketoacidosis and hyperosmolar hyperglycemic nonketotic coma. , 1990, Pediatric clinics of North America.

[42]  G. Giustina,et al.  Treatment of thyrotoxic storm by charcoal plasmaperfusion , 1989, Journal of endocrinological investigation.

[43]  K. Hogan,et al.  Difficult Laryngoscopy and Diabetes Mellitus , 1988, Anesthesia and analgesia.

[44]  K. Okamoto,et al.  Successful treatment of thyrotoxic crisis with plasma exchange , 1984, Critical care medicine.

[45]  S. Hoffman,et al.  Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. , 1984, The New England journal of medicine.

[46]  M. Magee,et al.  Management of decompensated diabetes. Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome. , 2001, Critical care clinics.

[47]  P. Marik,et al.  Hypothalamic-pituitary-adrenal insufficiency. , 2001, Critical care clinics.

[48]  G. Angelini,et al.  Perioperative Care of the Diabetic Patient , 2001 .

[49]  M. Ringel Management of hypothyroidism and hyperthyroidism in the intensive care unit. , 2001, Critical care clinics.

[50]  M. Weinmann Stress-induced hormonal alterations. , 2001, Critical care clinics.

[51]  P. Bollaert Stress doses of glucocorticoids in catecholamine dependency: a new therapy for a new syndrome? , 2000, Intensive Care Medicine.

[52]  H Wedel,et al.  Infarction : Long-Term Results From the Diabetes and Insulin-Glucose Infusion Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Glycometabolic State at Admission : Important Risk Marker of Mortality in , 1999 .

[53]  R. Jordan Myxedema coma. Pathophysiology, therapy, and factors affecting prognosis. , 1995, The Medical clinics of North America.

[54]  R. Williams,et al.  Williams Textbook of endocrinology , 1985 .